[go: up one dir, main page]

MA45976B1 - Récepteurs de lymphocytes t et thérapie immunitaire les utilisant - Google Patents

Récepteurs de lymphocytes t et thérapie immunitaire les utilisant

Info

Publication number
MA45976B1
MA45976B1 MA45976A MA45976A MA45976B1 MA 45976 B1 MA45976 B1 MA 45976B1 MA 45976 A MA45976 A MA 45976A MA 45976 A MA45976 A MA 45976A MA 45976 B1 MA45976 B1 MA 45976B1
Authority
MA
Morocco
Prior art keywords
col6a3
antigen
antigen recognition
relates
tcr
Prior art date
Application number
MA45976A
Other languages
English (en)
Other versions
MA45976A (fr
Inventor
Dominik Maurer
Leonie Alten
Sebastian Bunk
Steffen Walter
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60419980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45976(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA45976A publication Critical patent/MA45976A/fr
Publication of MA45976B1 publication Critical patent/MA45976B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des constructions de reconnaissance d'antigènes contre des antigènes col6a3. L'invention concerne en particulier de nouvelles molécules basées sur le récepteur des lymphocytes t (tcr) qui sont sélectifs et spécifiques pour l'antigène exprimé par la tumeur col6a3. Le tcr de l'invention, et les fragments de liaison à l'antigène col6a3 dérivés de celui-ci, sont utiles pour le diagnostic, le traitement et la prévention de maladies cancéreuses exprimant col6a3. L'invention concerne en outre des acides nucléiques codant pour les constructions de reconnaissance d'antigènes de l'invention, des vecteurs comprenant ces acides nucléiques, des cellules recombinantes exprimant les constructions de reconnaissance d'antigènes et des compositions pharmaceutiques comprenant les composés de l'invention.
MA45976A 2016-08-17 2017-07-04 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant MA45976B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US201662376632P 2016-08-18 2016-08-18
PCT/EP2017/066630 WO2018033291A1 (fr) 2016-08-17 2017-07-04 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant

Publications (2)

Publication Number Publication Date
MA45976A MA45976A (fr) 2021-05-19
MA45976B1 true MA45976B1 (fr) 2021-09-30

Family

ID=60419980

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45976A MA45976B1 (fr) 2016-08-17 2017-07-04 Récepteurs de lymphocytes t et thérapie immunitaire les utilisant

Country Status (18)

Country Link
US (2) US10550182B2 (fr)
EP (1) EP3500593B1 (fr)
JP (2) JP6964351B2 (fr)
CN (1) CN109563149A (fr)
AU (2) AU2017312361B2 (fr)
BR (1) BR112019001922A2 (fr)
CA (1) CA3031995A1 (fr)
CR (1) CR20190095A (fr)
DE (1) DE102016115246C5 (fr)
DK (1) DK3500593T3 (fr)
LT (1) LT3500593T (fr)
MA (1) MA45976B1 (fr)
MX (1) MX395287B (fr)
PE (1) PE20190477A1 (fr)
RS (1) RS62498B1 (fr)
SG (1) SG11201900955VA (fr)
TW (1) TWI775768B (fr)
WO (1) WO2018033291A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
WO2019086665A1 (fr) 2017-11-06 2019-05-09 Immatics Biotechnologies Gmbh Nouveaux récepteurs de lymphocytes t modifiés et immunothérapie les utilisant
JP7470640B2 (ja) 2018-02-09 2024-04-18 イマティクス ユーエス，アイエヌシー． Ｔ細胞を製造する方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US12195769B2 (en) 2018-06-19 2025-01-14 Dsm Ip Assets B.V. Lipolytic enzyme variants
JP7672979B2 (ja) * 2019-01-22 2025-05-08 アメリカ合衆国 Ｇ１２ｒ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
EP3941938A1 (fr) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Récepteurs de lymphocytes t spécifiques de l'antigène de maturation des lymphocytes b pour le traitement du cancer
WO2020191172A1 (fr) 2019-03-19 2020-09-24 Immatics US, Inc. Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US11975025B2 (en) 2019-05-27 2024-05-07 Immatics US, Inc. Viral vectors and use thereof in adoptive cellular therapy
SG11202112561UA (en) 2019-06-06 2021-12-30 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3186594A1 (fr) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Recepteurs de lymphocytes t modifies et leurs procedes d'utilisation
WO2022040631A1 (fr) 2020-08-21 2022-02-24 Immatics US, Inc. Procédés d'isolement de lymphocytes t sélectionnés cd8+
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
EP4392441A1 (fr) 2021-08-24 2024-07-03 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
EP4408468A4 (fr) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc Formats multiples de complexes moléculaires
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (fr) 2021-11-08 2023-05-11 Immatics US, Inc. Procédés de génération de sphéroïdes cellulaires
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
WO2023215825A1 (fr) 2022-05-05 2023-11-09 Immatics US, Inc. Procédés d'amélioration de l'efficacité d'un lymphocyte t
CN117946246B (zh) * 2023-02-23 2024-08-06 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2004511425A (ja) 2000-02-08 2004-04-15 ザ　ペン　ステート　リサーチ　ファウンデーション 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２
WO2006023382A2 (fr) * 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagene vi et cancer
EP1762575A1 (fr) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US9822162B2 (en) * 2013-07-15 2017-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
CA2954414A1 (fr) * 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Cellules modifiees pour therapie cellulaire adoptive
CN107075548B (zh) * 2014-11-05 2021-08-10 基因泰克公司 在细菌中产生双链蛋白质的方法

Also Published As

Publication number Publication date
CR20190095A (es) 2019-06-13
EP3500593B1 (fr) 2021-08-25
MA45976A (fr) 2021-05-19
EP3500593A1 (fr) 2019-06-26
WO2018033291A1 (fr) 2018-02-22
BR112019001922A2 (pt) 2019-07-09
DE102016115246B3 (de) 2017-12-14
US20180051080A1 (en) 2018-02-22
DE102016115246C5 (de) 2018-12-20
AU2017312361B2 (en) 2020-12-10
CN109563149A (zh) 2019-04-02
AU2017312361A1 (en) 2019-02-28
PE20190477A1 (es) 2019-04-04
TW201806973A (zh) 2018-03-01
US10550182B2 (en) 2020-02-04
US10526407B2 (en) 2020-01-07
RS62498B1 (sr) 2021-11-30
LT3500593T (lt) 2021-11-25
SG11201900955VA (en) 2019-03-28
US20180319884A1 (en) 2018-11-08
AU2021201518A1 (en) 2021-04-01
DK3500593T3 (da) 2021-11-01
MX2019001769A (es) 2019-07-08
JP2019528061A (ja) 2019-10-10
JP6964351B2 (ja) 2021-11-10
TWI775768B (zh) 2022-09-01
CA3031995A1 (fr) 2018-02-22
MX395287B (es) 2025-03-25
JP2021184729A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
MA49236B1 (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
MA47932B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
MX2022015821A (es) Nuevos receptores de celulas t y usos de los mismos.
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
MY205262A (en) Novel t cell receptors and immune therapy using the same
WO2018172533A3 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant contre des cancers positifs à prame
PH12019500312A1 (en) T cell receptors and immune therapy using the same
EA202090372A1 (ru) Универсальные соединения авт и их применение
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
EA202192252A1 (ru) Высокоавидные т-клеточные рецепторы к wt1 и их применения
WO2023280297A9 (fr) Anticorps cd19 et son application
AR113834A1 (es) Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
EA202090712A1 (ru) Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием
MY195101A (en) Novel T Cell Receptors and Immune Therapy Using the Same
EA202190186A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same
EA202190555A1 (ru) Рестриктированные по в*44 пептиды для применения в иммунотерапии раковых заболеваний и связанные с ними способы
EA202190169A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по b*07 пептидами и комбинациями пептидов и относящиеся к ней способы
EA202191411A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по b*08 пептидами и комбинациями пептидов и связанные с ними способы
EA201991139A1 (ru) Новые т-клеточные рецепторы и иммунотерапия с их применением